LEADER 03756oam 2200589 450 001 9910830255203321 005 20230629234225.0 010 $a1-119-56468-9 010 $a1-119-56466-2 010 $a1-119-56469-7 035 $a(CKB)4100000011248672 035 $a(OCoLC)1155482711 035 $a(MiAaPQ)EBC6452693 035 $a(EXLCZ)994100000011248672 100 $a20210318h20212021 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aBiologics, biosimilars, and biobetters $ean introduction for pharmacists, physicians and other health practitioners /$fedited by Iqbal Ramzan 210 1$aHoboken, New Jersey :$cWiley,$d2021. 210 4$dİ2021 215 $a1 online resource (xii, 302 pages) $cillustrations (chiefly colour) 311 1 $a1-119-56465-4 311 08$aPrint version: Biologics, biosimilars, and biobetters First edition. Hoboken, NJ : Wiley, 2020. 9781119564652 (DLC) 2020023346 327 $aInnovator Biologics, Biosimilars and Biobetters : Terminology, Nomenclature and Definitions -- Approved Biologic Medicines and Biosimilars in Major Regulatory Jurisdictions -- Status of Biologic Drugs in Modern Therapeutics-Targeted Therapies vs Small Molecule Drugs -- Major Classes of Biotherapeutics -- Drug Targets for Biologics -- Pivotal Biology, Chemistry, Biochemistry and Biophysical Concepts of Biologics and Biosimilars -- Biosimilarity and Interchangeability of Biologic Drugs- General Principles, Biophysical Tests and Clinical Requirements to Demonstrate Biosimilarity -- Pharmacokinetics of Biologics -- Pharmacogenomics of Biologics -- International Regulatory Processes and Policies for Innovator Biologics, Biosimilars and Biobetters -- Pharmacovigilance of Innovator Biologics and Biosimilars -- Pharmacoeconomics of Biologic Medicines and Biosimilars / Gregory Reardon -- New Emerging Biotherapies : Cutting-Edge Research to Experimental Therapies -- Optimising Use of Biologic Medicines Using a Quality Use of Medicines Approach -- Knowledge Areas and Competency Standards on Biologic Medicines for Pharmacists and Pharmacy Students -- A Checklist for Pharmacists on Biologics and Biosimilars - Tips to Enhance Patient-Centred Discussions. 330 $a"Biologics (and their interchangeable equivalents, biosimilars) and their more efficacious successors (biobetters) are taking up a larger share of the therapeutics drug market compared to small molecule drugs. They are potent, more expensive, and complex in their therapeutic and clinical utility. Pharmacists are the primary health care professionals who will provide advice to physicians, other health practitioners and patients on these drugs as governments and other third party payers attempt to contain their costs by introducing interchangeable products"--$cProvided by publisher. 606 $aBiological products 606 $aBiologicals 606 $aPharmaceutical biotechnology 606 $aBiological Products$3(DNLM)D001688 606 $aBiosimilar Pharmaceuticals$3(DNLM)D059451 606 $aBiopharmaceutics$3(DNLM)D001702 606 $aBiologicals$2fast$3(OCoLC)fst00832374 615 0$aBiological products. 615 0$aBiologicals. 615 0$aPharmaceutical biotechnology. 615 12$aBiological Products. 615 22$aBiosimilar Pharmaceuticals. 615 22$aBiopharmaceutics. 615 7$aBiologicals. 676 $a615.7 702 $aRamzan$b Iqbal$f1951- 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 801 2$bDLC 906 $aBOOK 912 $a9910830255203321 996 $aBiologics, biosimilars, and biobetters$94119693 997 $aUNINA